Evidence map›Paper›PMID 40837697›Full record

ArticleInternational journal of nanomedicine2025

Comparative Evaluation of Three Nanoparticle Vaccines Targeting the Prefusion F Protein of Respiratory Syncytial Virus: Immunogenicity and Protective Efficacy.

Jie Jiang, Hongqiao Hu, Lei Cao, Naiying Mao, Zhen Zhu, Na Wang, Yuqing Shi, Hai Li, Yan Zhang

Abstract readComparative StudyEvaluation StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jie JiangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Disease, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.ORCID 0009-0002-5341-3311
Hongqiao HuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Disease, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
Lei CaoNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Disease, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
Naiying MaoNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Disease, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
Zhen ZhuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Disease, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
Na WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Disease, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
Yuqing ShiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Disease, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
Hai LiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Disease, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
Yan ZhangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Disease, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate the immunogenic potential of three different nanoparticle (NP) platforms for respiratory syncytial virus (RSV) prefusion (pre-F) protein vaccines. Methods: Three NP platforms-24-mer ferritin (Fe), 60-mer lumazine synthase (LuS), and 120-subunit I53-50-were engineered to display RSV pre-F trimers (DS2) via SpyTag-SpyCatcher (ST-SC) conjugation (DS2-Fe, DS2-LuS) or direct genetic fusion (DS2-I53-50). The assembled particles were characterized using size-exclusion chromatography (SEC), SDS-PAGE, electron microscopy (EM), and dynamic light scattering (DLS). Antigenicity was evaluated using enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR) with prefusion-specific neutralizing antibodies. Immunogenicity and protective efficacy were evaluated in BALB/c mice following a prime-boost immunization, with analyses of humoral and cellular immune responses as well as post-challenge protection. Results: All three NP platforms successfully displayed the DS2 antigen while preserving its prefusion conformation. Notably, DS2-I53-50 demonstrated superior assembly quality and particle homogeneity relative to DS2-Fe and DS2-LuS. Compared to soluble DS2, all three DS2-NPs exhibited enhanced binding affinity (7- to 12-fold increase) to prefusion-specific antibodies (D25, AM14). In vivo, all DS2-NPs elicited higher levels of RSV-specific neutralizing antibodies and induced a more balanced Th1/Th2 immune response, with DS2-I53-50 generating significantly greater neutralizing antibody titers (1.7- to 2.4-fold increase) against both prototype RSV strains (LONG, 18537) and circulating genotypes (ON1, BA9). Immune cell profiling further revealed that all three DS2-NPs enhanced germinal center formation, facilitated follicular dendritic cell recruitment, and expanded memory T cell populations. Following RSV challenge, all DS2-NPs vaccines conferred significant protection, evidenced by accelerated weight recovery, reduced lung viral loads, and mitigated pulmonary pathology. Among them, DS2-I53-50 provided the most robust protection, achieving a 3.7-log reduction in viral titers and minimal lung pathology. Conclusion: NP platforms significantly enhanced the immunogenicity of RSV DS2 antigens, with DS2-I53-50 eliciting the strongest immune responses and protective efficacy. These findings underscore the potential of rationally designed NP-based vaccines for RSV.

Indexed as

NanovaccinesRespiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesViral Fusion ProteinsAnimalsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralDisease Models, AnimalFemaleHEK293 CellsHumansImmunogenicity, VaccineMiceMice, Inbred BALB CAntibodies, NeutralizingAntibodies, ViralAntigens, ViralNanovaccinesRespiratory Syncytial Virus VaccinesViral Fusion ProteinsferritinI53-50immunogenicitylumazine synthasenanoparticle vaccineprefusion F proteinprotective efficacyrespiratory syncytial virusRSV

Identifiers

PMID40837697
PMCPMC12363979

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.